Lapisteride
Based on 1 Customer Validation
Lapisteride (CS 891) is an orally active 5α-reductase inhibitor. Lapisteride can inhibit 5α-reductaseactivity in the hair follicles (HF). Lapisteride can be used in prostatic hyperplasia and androgenic alopecia research.
For research use only. We do not sell to patients.
- Purity: 99.0%
- CAS No.: 142139-60-4
- Formula: C29H40N2O3
- Molecular Weight:464.64
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Chemical Information
-
CAS No. 142139-60-4
-
Appearance Solid
-
Molecular Weight 464.64
-
Formula C29H40N2O3
-
Color White to off-white
-
SMILES
C[C@@]12[C@](CC[C@@H]2C(NC(C)(C3=CC=C(C=C3)OC)C)=O)([H])[C@@]4([H])[C@@](CC1)([H])[C@@]5([C@@](NC(C=C5)=O)([H])CC4)C
-
Synonyms
CS 891
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
Ethanol : 100 mg/mL (215.22 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yada S, et al. Solid phase transition of CS-891 enantiotropes during grinding. Int J Pharm. 2003 Apr 14;255(1-2):69-79. [Content Brief]
[2]. Niiyama S, et al. The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol. 2000 Dec;10(8):593-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.1522 mL | 10.7610 mL | 21.5220 mL | 53.8051 mL |
| 5 mM | 0.4304 mL | 2.1522 mL | 4.3044 mL | 10.7610 mL | |
| 10 mM | 0.2152 mL | 1.0761 mL | 2.1522 mL | 5.3805 mL | |
| 15 mM | 0.1435 mL | 0.7174 mL | 1.4348 mL | 3.5870 mL | |
| 20 mM | 0.1076 mL | 0.5381 mL | 1.0761 mL | 2.6903 mL | |
| 25 mM | 0.0861 mL | 0.4304 mL | 0.8609 mL | 2.1522 mL | |
| 30 mM | 0.0717 mL | 0.3587 mL | 0.7174 mL | 1.7935 mL | |
| 40 mM | 0.0538 mL | 0.2690 mL | 0.5381 mL | 1.3451 mL | |
| 50 mM | 0.0430 mL | 0.2152 mL | 0.4304 mL | 1.0761 mL | |
| 60 mM | 0.0359 mL | 0.1794 mL | 0.3587 mL | 0.8968 mL | |
| 80 mM | 0.0269 mL | 0.1345 mL | 0.2690 mL | 0.6726 mL | |
| 100 mM | 0.0215 mL | 0.1076 mL | 0.2152 mL | 0.5381 mL |